A 2-week journey with Pyri, which is producing positive effects on hair texture and reduced shedding; Minoxidil and derma needling are being used as treatments.
The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.
The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.
The user saw no hair loss improvement for a year using 1mg finasteride and 5% minoxidil. They experienced better results after reducing finasteride to 0.25mg, adding a derma pen treatment, and applying a solution with minoxidil and melatonin.
The conversation discusses a new 0.3% tretinoin topical launched by MinoxidilMax for mixing with other solutions, with some users expressing concern about potential skin irritation compared to lower concentrations. MinoxidilMax has also released other products like topical Dutasteride and RU58841.
A 21-year-old experienced erectile dysfunction after using finasteride and consuming multiple drugs, including MDMA, LSD, and weed. He plans to quit finasteride and weed, improve his habits, and consider alternative treatments like mesotherapy with dutasteride.
A user humorously suggested smoking minoxidil in a blunt as an alternative hair growth method, sparking a satirical discussion on unconventional and unsafe ways to use minoxidil. The conversation included various suggestions like oral pills, rectal administration, and other absurd methods, with some users warning against the dangers of such practices.
The conclusion of the conversation is that the user, Lead_Tasso, is expressing gratitude for the community's help in restoring their confidence in treating hair loss. They have been using finasteride (fin) and minoxidil (min) and have also been taking hair and nail vitamins.
A user found that scalp itch might be linked to inflammation rather than DHT alone and noticed hair improvement with certain cancer drugs. They also discovered that black seed oil relieved their scalp itch and are experimenting with a mix of essential oils for dry scalp, questioning if oils affect minoxidil absorption.
The conversation is about finding effective hair loss treatments without using finasteride or dutasteride. Suggested treatments include topical minoxidil, oral minoxidil, microneedling, PRP, and RU58841.
A 30-year-old man saw improved hair density and texture after three months using Minoxidil, Finasteride, and ketoconazole shampoo, despite initial side effects. He experienced increased body hair and libido and is satisfied with the results despite the high cost in Turkey.
Red light therapy has shown promising results in hair regrowth for the user, who avoids minoxidil and finasteride due to side effects. The user follows a healthy lifestyle with diet, exercise, and sauna use, and will continue monitoring the therapy's effectiveness.
A user experimented with applying pure rosemary oil to a single hair strand twice daily, observing increased thickness and pigmentation, but questioned if the oil or the application method caused the change. Some users noted rosemary oil might be as effective as 2% minoxidil for hair growth, though others warned about potential harm from using undiluted oil.
Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.
PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.
New hair loss treatments like GT20029 and PP405 could potentially replace minoxidil and finasteride, offering better results with fewer side effects. However, current treatments like finasteride and minoxidil are still effective for many, despite concerns about side effects.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
Finasteride and minoxidil are recommended as first-line treatments for hair loss, with dutasteride and oral minoxidil as stronger options if needed. Hair transplants should only be considered after achieving stability with medication, and non-surgical options are suggested if medications are ineffective.
Results for PP405 are expected next year, with concerns about its pricing and potential black market availability. Some users believe it may be slightly more effective than finasteride and dutasteride, and combining it with treatments like minoxidil and microneedling could be beneficial.
A pharmacy student proposed a hair loss treatment using minoxidil, finasteride, clascoterone, and tretinoin, aiming for high effectiveness with minimal side effects. Reactions were mixed, with some questioning its feasibility and others showing interest.
A serum with oleic and palmitoleic acids shows promise for hair regrowth in mice, but its effectiveness in humans is unproven. Minoxidil and finasteride remain the recommended treatments.
Finasteride users may have an increased risk of depression, anxiety, and suicidal thoughts, though some attribute these issues to hair loss itself. The link between finasteride and mental health effects is debated, with varying user experiences.
PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.
JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.
The user is considering starting oral minoxidil for hair regrowth, debating between 2.5mg and 5mg doses, while already using topical minoxidil, dutasteride, and ketoconazole shampoo. Users suggest starting with a lower dose to monitor side effects, with some recommending trying finasteride first.
The conversation covers aggressive hair regrowth treatments like Dutasteride, Minoxidil (oral and topical), RU58841, microneedling, and ketoconazole shampoo. It also mentions PRP, laser therapy, GHK-Cu injections, and hormone therapy for maximum regrowth.
PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.
PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.
Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.
Finasteride and dutasteride are significantly cheaper in India, leading to substantial savings for users. There are discussions on the effectiveness of oral minoxidil and finasteride for hair loss, with concerns about the quality of generic medications.